Skip to main content
SpringerLink
Log in

Therapie der Sepsis

  • Chapter
Evidenzbasierte Medizin in Anästhesie und Intensivmedizin

  • 904 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abraham E et al (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. A randomized controlled trial. JAMA 290: 238–247

    Article  PubMed  CAS  Google Scholar 

  2. Abraham E et al (2003) Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa grop lia secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 31: 718–728

    PubMed  CAS  Google Scholar 

  3. Abraham E et al. (1995) Efficacy and safety of monoclonal antibody to human tumor-necrosis factor αin patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-α Mab Sepsis Study Group. JAMA 273: 934–941

    Article  PubMed  CAS  Google Scholar 

  4. Abraham E (2001) Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: arandomized, double-blind, placebo-controlled, mulitcenter phase III trial with 1342 patients. Crit Care Med 29: 503–510

    PubMed  CAS  Google Scholar 

  5. Alberti C et al. (2002) Epidemiology of sepsis and infection in ICU patients from an fnternational multicentre cohort study. Intensive Care Med 28: 108–121

    PubMed  Google Scholar 

  6. Alberti C, Brun-Buisson C (2003) Epidemiology of inefction and sepsis: Areview. Advances in Sepsis 3: 45–55

    Google Scholar 

  7. Alejandria MMt et al (2001) Intravenous immuneglobuline for treating sepsis and septic shock. The Cochrane Library 2.; Oxford: Update Software

    Google Scholar 

  8. Angus DC et al (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303–1310

    PubMed  CAS  Google Scholar 

  9. Angus DC et al (2002) The effects of drotrecogin alfa (activated) on long-term survival after severe sepsis. Chest 122(Suppl.): 51S

    Google Scholar 

  10. Angus DC, Crowther MA (2003) Unraveling severe sepsis. Why did OPTIMIST fail and what’s next. JAMA 290: 256–258

    Article  PubMed  Google Scholar 

  11. Annane D (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients in septic shock. JAMA 288: 862–871

    Article  PubMed  CAS  Google Scholar 

  12. Annane D et al (2000) A3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283: 1038–1045

    Article  PubMed  CAS  Google Scholar 

  13. Annane D, Cavaillon JM (2003) Corticosteroids in sepsis: From bench to bedside. Shock 20: 197–207

    PubMed  CAS  Google Scholar 

  14. Arich C et al. (1987) Comparison of the efficacy of cefotaxime alone and the combination cefazolin-tobramycin in the treatment of enterobacterial septicemia. Pathol Biol (Paris) 35: 613–615

    PubMed  CAS  Google Scholar 

  15. Barie PS, et al. (2003) Drortecogin alfa (activated) has a favorable benefit/risk profile in surgical patients with severe sepsis

    Google Scholar 

  16. Bernard GR et al. (2003) Safety assesment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 7: 155–163

    Article  PubMed  Google Scholar 

  17. Bernard GR et al. (2001) Efficacy and safety of recombinant human activated protein C for sever sepsis. N Engl J Med 344: 699–709

    Article  PubMed  CAS  Google Scholar 

  18. Bilton BD et al. (1998) Aggressive surgical management of necrotizing fasciitis serves to decresemortality: a retrospective study. Am Surg 64: 397–400

    PubMed  CAS  Google Scholar 

  19. Bochud PY, Glauser MP, Calandra T (2001) Antibiotics in sepsis. Intensive Care Med 27: S33–S48

    PubMed  Google Scholar 

  20. Bodmann KF, Vogel F (2001) Antimikrobielle Therapie der Sepsis. Chemotherapie J 10: 43–56

    Google Scholar 

  21. Bollaert PE et al. (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26: 645–650

    PubMed  CAS  Google Scholar 

  22. Bone RC (1991) Critical evaluation of new agents for the treatment of sepsis. JAMA 266: 1686–1691

    PubMed  CAS  Google Scholar 

  23. Bone RC et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644–1655

    PubMed  CAS  Google Scholar 

  24. Bone RC, Fisher CJ, Clemmer TP (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653–658

    Article  PubMed  CAS  Google Scholar 

  25. Briegel J et al (1999) Stress doses of hydrocortison reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27: 723–732

    PubMed  CAS  Google Scholar 

  26. Brun-Buisson C et al. (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU group for severe sepsis. JAMA 274: 968–974

    Article  PubMed  CAS  Google Scholar 

  27. Cometta A, Baumgartner JD (1994) Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicinfortreatment of severe infections in non-neutropenic patients. Antimicrob Agents Chemother 38: 1309–1013

    PubMed  CAS  Google Scholar 

  28. Cooper MS, Stewart PM (2003) Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348: 727–734

    PubMed  CAS  Google Scholar 

  29. Cronin L, Cook DJ, Carlet J (1995) Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995 23: 1430–1439

    PubMed  CAS  Google Scholar 

  30. Dhainnaut JF et al. (2003) Drotrcogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29: 894–903

    Google Scholar 

  31. Eichacker PQ et al. (2002) Riskand efficacy of antiinflammatory agents. Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166: 1197–1205

    PubMed  Google Scholar 

  32. Eklund AE, Nord CE (1993) A randomized multicenter trial of piperacillin/tazobactam vs. imipenem/cilastatin in the treatment of severe intra-abdominal infections.Swedish Study Group. J Antimicrob Chemother [Suppl.A]: 79–85

    Google Scholar 

  33. Ely EW et al (2003) Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31: 12–19

    PubMed  CAS  Google Scholar 

  34. Ely EW, Bernard GR, Vincent JL (2002) Activated protein C for severe sepsis.N Engl J Med 347: 1035–1036

    Article  PubMed  Google Scholar 

  35. Extermann M et al. (1995) Initial treatment of sepsis in non-neutropenic patients: ceftazidime alone vs. »best guess« combined antibiotic therapy. Chemotherapy 41:306–315

    PubMed  CAS  Google Scholar 

  36. Freischlag JA, Ajalat G, Busuttil RW (1985) Treatment of necrotizing soft tissue infections. Aneed for a new approach. Am J Surg 149: 751–755

    PubMed  CAS  Google Scholar 

  37. Friedman, G., Silva, E., and Vincent, J. L. Has the Mortality of Septic Shock Changed With Time. Crit Care Med. 1998;26(12): 2078–2086

    PubMed  CAS  Google Scholar 

  38. Gatell J M (1988) Nosocomial Bacteremia in a Large Spanish Teaching Hospital: Analysis of Factors Influencing Prognosis. Rev Infect Dis 10: 203–210

    PubMed  CAS  Google Scholar 

  39. Gerzof SG et al (1981) Percutaneous catheter drainage of abdominal abscesses. A five year experience. N Engl J Med 305: 653–657

    Article  PubMed  CAS  Google Scholar 

  40. Gerzof SG et al (1985) Expanded criteria for percutaneous abscess drainage. Arch Surg 120: 227–232

    PubMed  CAS  Google Scholar 

  41. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138–150

    Article  PubMed  CAS  Google Scholar 

  42. Jaccard C et al. (1998) Prospective randomized comparison of imipenem/cilastatin and piperacillen/tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 42: 2966–2972

    PubMed  CAS  Google Scholar 

  43. Joyce DE, Grinnell BW (2002) Recombinat human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kB. Crit Care Med 30[Suppl.]: S288–S293

    PubMed  CAS  Google Scholar 

  44. Knaus WA et al. (1996) Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The RhIL1-ra Phase IIISepsis Syndrome Study Group. Crit Care Med 24: 46–56

    PubMed  CAS  Google Scholar 

  45. Krumpe PE et al. (1999) Intravenous and oral mono-or combination treament of severe infections: ciprofloxacin vs. standard antibiotic therapy.Ciprofloxacib Study Group. J Antimicrob Chemother [Suppl.A]: 117–128

    Google Scholar 

  46. Lefering R, Neugebauer EAM (1995) A steroid controversy in sepsis and septic shock: A meta-analysis. Crit Care Med 1995 23: 1294–1303

    PubMed  CAS  Google Scholar 

  47. Leone M et al. (203) Empirical antibiotic therapyof sptic shock patients. Adequancy and impact on the outcome. Crit Care Med 31: 462–467

    Google Scholar 

  48. Malmberg K (1997) Prospective randomised study of intensive insulin treatment on lonf term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314: 1512–1515

    PubMed  CAS  Google Scholar 

  49. Marik PE, Zaloga GP (2003) Adrenal insufficiency inseptic shock. Crit Care Med 31: 141–145

    PubMed  CAS  Google Scholar 

  50. Marshall JC (2001) Inflammation, coagulation, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 29[Suppl.]: S99–S106.863

    PubMed  CAS  Google Scholar 

  51. Mc Cormick PA et al. (1997) A prospective randomized trial of ceftazidime vs. netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. Hepathology 25: 833–836

    Article  CAS  Google Scholar 

  52. Meehan TP et al (1997) Quality of care, process, ant outcomes in elderly patients with pneumonia. JAMA 278: 2080–2084

    Article  PubMed  CAS  Google Scholar 

  53. Mesotten D et al. (2004) Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab 89: 219–226

    PubMed  CAS  Google Scholar 

  54. Mier J et al (1997) Early vs. late necrosectomy in severe necrotizing pancreatitis. Am J Surg 173: 71–75

    Article  PubMed  CAS  Google Scholar 

  55. Miller JD (1983) The importance of early diagnosis and surgical treatment of necrotizing fasciitis. Surg Gynecol Obstet 157: 197–200

    PubMed  CAS  Google Scholar 

  56. Mouton Y et al. (1990) Prospective randomized, controlled study of imipenem-cilastatin vs. cefotaxime-amikacin in the treatment of lower respiratory tract infection and septicemia at intensive care untis. Presse Méd 19: 607–612

    PubMed  CAS  Google Scholar 

  57. Mouton Y, Beuscart C (1995) Empirical monotherapy with meropenem in seriousbacterial infections.Meropenem Study Group. J Antimicrob Chemother 36[Suppl. A]: 145–156

    PubMed  CAS  Google Scholar 

  58. Muckart DJ et al. (1997) American college of chest physicians/society of critical care medicine consensus conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 25: 1789–95

    PubMed  CAS  Google Scholar 

  59. Neilson AR et al. (2003) Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 18: 217–227

    Article  PubMed  Google Scholar 

  60. Niederman MS (2003) Appropriateuse of antmicrobial agents: Challenges and strategies for improvement. Crit Care Med 31: 608–616

    PubMed  Google Scholar 

  61. Oblinger MJ et al (1982) Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections. Rev Infect Dis 4[Suppl.]: S639–S649

    PubMed  Google Scholar 

  62. Olak JO et al. (1986) Operative vs. precutaneous drainage of intra-abdominal abscesses. Arch Surg 121: 141–146

    PubMed  CAS  Google Scholar 

  63. Pittet D et al (1993) Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Med 19: 265–72

    Article  PubMed  CAS  Google Scholar 

  64. Pittet D et al. (1995) Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: Incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 21: 302–9

    Article  PubMed  CAS  Google Scholar 

  65. Rangel-Frausto M S et al. (1995) The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273: 117–23

    Article  PubMed  CAS  Google Scholar 

  66. Rea WJ, Wyrick WJ (1970) Necrotizing fasciitis. Ann Surg 172: 957–964

    PubMed  CAS  Google Scholar 

  67. Reinhart K et al. (2001) Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 29: 765–769

    PubMed  CAS  Google Scholar 

  68. Rello J et al. (1994) Nosocomial bacteremia in a medicalsurgical intensive care unit: epidemiologic characteristics and factor influencing mortality in 111 episodes. Intensive Care Med 20: 94–98

    PubMed  CAS  Google Scholar 

  69. Saini S et al (1983) Improvedlocalization and survival in patients with intra-abdominal abscesses. Am J Surg 145: 136–142

    Article  PubMed  CAS  Google Scholar 

  70. Salvo I et al (1995) The italian SEPSIS study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 21[Suppl 2]: S244–S249

    PubMed  Google Scholar 

  71. Schumer W (1976) Steroids in the treatment of clinicalseptic shock. Ann Surg 184: 333–341

    PubMed  CAS  Google Scholar 

  72. Siegel JP (2002)Assesing the use of activated protein Cin the treatment of severe sepsis. N Engl J Med 347: 1030–1034

    Article  PubMed  Google Scholar 

  73. Solberg CO, Sjursen H (1995) Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime,alone or combined with amikacin. J Antimicrob Chemother 36[Suppl. A]: 157–166

    PubMed  CAS  Google Scholar 

  74. Sudarsky LA et al (1987) Improved results from standardized approach in treating patients with necrotizing fasciitis. Ann Surg 206: 661–665

    PubMed  CAS  Google Scholar 

  75. The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of sepsis. N Engl J Med 317: 659–665

    Google Scholar 

  76. Van den Berghe G et al (1999) Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patientswith protracted critical illness. J Clin Endocrinol Metab 84: 1311–1323

    PubMed  Google Scholar 

  77. Van den Berghe G et al (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345: 1359–1367

    PubMed  Google Scholar 

  78. Van den Berghe G et al (2003) Outcome benefit of intensive insulin therapy in the criticallyill: Insulin dose vs. glcemic control. Crit Care Med 31: 359–366

    PubMed  Google Scholar 

  79. Vincent JL et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure. Intensive Care Med 22: 707–710

    PubMed  CAS  Google Scholar 

  80. Vincent JL et al (2002) Reducing mortality in sepsis: new directions. Crit Care 6[Suppl.]: S1–S18

    PubMed  Google Scholar 

  81. Vincent JL et al. (2003) Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31: 834–840

    PubMed  CAS  Google Scholar 

  82. Voros D et al (1993) Role of earlyand extensive surgery in the treatment of severe necrotizing soft tissue infections. Br J Surg 80: 1190–1191

    PubMed  CAS  Google Scholar 

  83. Warren BL et al (2001) Caring for critical ill patient. Highdose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286: 1869–1878

    PubMed  CAS  Google Scholar 

  84. Werdan K (2001) Intravenous immunoglobulinfor prophylais and therapy of sepsis. Curr Opin Crit Care 7: 354–361

    PubMed  CAS  Google Scholar 

  85. White NJ et al. (1989) Halving of mortality of severe melioidosis by ceftazidime. Lancet II: 697–701

    Google Scholar 

  86. Wichmann WM et al. (2000) Incidence and mortality of severe sepsis in surgical sntensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med 26: 167–72

    Article  PubMed  CAS  Google Scholar 

  87. Yan SB, Dhainaut JF (2001) Activated protein C vs. protein C in severe sepsis. Crit Care Med 29[Suppl.]: S69–S74

    PubMed  CAS  Google Scholar 

  88. Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 25: 1095–1100

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Boehringer Ingelheim Pharma GmbH, Klinische Forschung, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany

    PD Dr. L. de Rossi

Authors
  1. PD Dr. L. de Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

de Rossi, L. (2005). Therapie der Sepsis. In: Evidenzbasierte Medizin in Anästhesie und Intensivmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26858-8_4

Download citation

  • DOI: https://doi.org/10.1007/3-540-26858-8_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20042-0

  • Online ISBN: 978-3-540-26858-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation